VBIV - חוב כולל להון VBI Vaccines

The VBI Vaccines Inc. (VBIV) price chart demonstrates a total debt-to-equity ratio of 0.00. The business relies on domestic government cycles, establishing it as a defensive asset independent of global crises. An efficiency advantage in Hepatitis B vaccines allows the company to exercise pricing power. A diverse pipeline of drugs at various testing stages minimizes potential losses from regulatory decisions.

For the investor, this ratio serves as a measure of financial stability, comparing total liabilities against equity to assess bankruptcy risks. Amid liquidity shortages at VBI Vaccines Inc. (VBIV) and costly R&D, it reveals a critical dependence on borrowed capital, which is clearly demonstrated by the shift in the business leverage ratio on the GURU.Markets platform as an indicator of the company's solvency.